Results 191 to 200 of about 370,325 (328)
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin +6 more
wiley +1 more source
Targeting CLEC4E in immunosuppressive tumour‐associated macrophages via BET inhibition
Clinical and Translational MedicineBackground Immunosuppressive tumour‐associated macrophages (TAMs) represent a promising target for cancer immunotherapy; however, existing TAM‐directed therapies have shown limited clinical efficacy. C‐type lectin domain family 4 member E (CLEC4E), a pro‐
Mengting Liao +10 more
doaj +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge +5 more
wiley +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin +4 more
wiley +1 more source
Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
JEADV Clinical Practice, EarlyView.ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson +4 more
wiley +1 more source
Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists
JEADV Clinical Practice, EarlyView.ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, EarlyView.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
The association between psoriasis and nonalcoholic fatty liver disease: Mediation analysis involving inflammatory biomarkers among U.S. adults. [PDF]
PLoS OneWang X +8 more
europepmc +1 more source
Approach to Nail Pitting in Pediatric and Adolescent Patients: A Dermatology Perspective
JEADV Clinical Practice, EarlyView.ABSTRACT This narrative review aims to discuss the etiologies of nail pitting in pediatric and adolescent patients, while providing a framework for further evaluation of possible underlying systemic conditions and their clinical findings from a dermatologic standpoint.
Elizabeth Botto +3 more
wiley +1 more source